The Clinical Efficacy of Adding Ceftazidime/Avibactam to Standard Therapy in Treating Infections Caused by Carbapenem-Resistant <i>Klebsiella pneumonia</i> with blaOXA-48-like Genes

The Clinical Efficacy of Adding Ceftazidime/Avibactam to Standard Therapy in Treating Infections Caused by Carbapenem-Resistant <i>Klebsiella pneumonia</i> with blaOXA-48-like Genes

Ceftazidime/avibactam (CAZ-AVI) is FDA-approved for managing infections caused by resistant gram-negative bacilli, particularly infections via carbapenem-resistant <i>Enterobacterales</i> pathogens. The clinical data are still limited, particularly those in Saudi Arabia. The present stud...

Full description

Bibliographic Details
Main Authors: Al Maamon R. Abu Jaber, Bilgen Basgut, Ali Abdullah Hawan, Ali Amer Al Shehri, Sultan Ahmad AlKahtani, Nehad J. Ahmed, Abdikarim Abdi
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Antibiotics
Subjects:
carbapenem resistance
<i>Klebsiella pneumonia</i>
OXA-48-like genes
ceftazidime/avibactam
clinical efficiency
Online Access:https://www.mdpi.com/2079-6382/13/3/265

Internet

https://www.mdpi.com/2079-6382/13/3/265

Similar Items